Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Business Wire•11/10/2026•17:00 ET
5
Key Highlights
- ➤Mirum (MIRM) will host an October 12 investor call for EXPAND topline results
- ➤Phase 3 EXPAND evaluates LIVMARLI in ultra-rare cholestatic liver diseases
- ➤Study includes patients aged 6 months or older, including biliary atresia
- ➤LIVMARLI is approved for Alagille syndrome and progressive familial intrahepatic cholestasis
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI(®) (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI(®) (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.
Get started
Create a free account to read the full story.